Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome

Abstract : BACKGROUND: We aimed to evaluate clinical symptoms in subjects with irritable bowel syndrome receiving Saccharomyces cerevisiae in a randomized double-blind placebo-controlled clinical trial. METHODS: Overall, 179 adults with irritable bowel syndrome (Rome III criteria) were randomized to receive once daily 500 mg of Saccharomyces cerevisiae, delivered by one capsule (n = 86, F: 84%, age: 42.5 ± 12.5), or placebo (n = 93, F: 88%, age: 45.4 ± 14) for 8 weeks followed by a 3-week washout period. After a 2-week run-in period, cardinal symptoms (abdominal pain/discomfort, bloating/distension, bowel movement difficulty) and changes in stool frequency and consistency were recorded daily and assessed each week. A safety assessment was carried out throughout the study. RESULTS: The proportion of responders, defined by an improvement of abdominal pain/discomfort, was significantly higher (p = 0.04) in the treated group than the placebo group (63% vs 47%, OR = 1.88, 95%, CI: 0.99-3.57) in the last 4 weeks of treatment. A non-significant trend of improvement was observed with Saccharomyces cerevisiae for the other symptoms. Saccharomyces cerevisiae was well tolerated and did not affect stool frequency and consistency. CONCLUSION: Saccharomyces cerevisiae is well tolerated and reduces abdominal pain/discomfort scores without stool modification. Thus, Saccharomyces cerevisiae may be a new promising candidate for improving abdominal pain in subjects with irritable bowel syndrome.
Liste complète des métadonnées
Contributeur : Anthony Herrada <>
Soumis le : lundi 17 juin 2019 - 09:35:35
Dernière modification le : jeudi 4 juillet 2019 - 17:18:37

Lien texte intégral



Guillaume Pineton de Chambrun, Christel Neut, Amélie Chau, Murielle Cazaubiel, Fanny Pelerin, et al.. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and Liver Disease, WB Saunders, 2015, 47 (2), pp.119-124. ⟨10.1016/j.dld.2014.11.007⟩. ⟨hal-02157534⟩



Consultations de la notice